Multidrug resistance in cancer: role of ATP–dependent transporters

[1]  J. Doroshow,et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.

[2]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[3]  Zhe-Sheng Chen,et al.  Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. , 2001, The Journal of biological chemistry.

[4]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[5]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[6]  T. Grogan,et al.  Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Atkins,et al.  Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Fojo,et al.  The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[10]  I. Schoots,et al.  Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. , 2001, Molecular pharmacology.

[11]  R. Advani,et al.  A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[13]  K. Tew,et al.  Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). , 2001, Cancer research.

[14]  H. Kotani,et al.  Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. , 2001, Cancer research.

[15]  R. B. Campbell,et al.  Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Grogan,et al.  Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Giuliano,et al.  Ceramide glycosylation potentiates cellular multidrug resistance , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  R. Jain.  Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[19]  J. Kahng,et al.  Expression of Functional Markers in Acute Nonlymphoblastic Leukemia , 2001, Acta Haematologica.

[20]  C. Ackerley,et al.  Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Ho,et al.  P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. , 2001, Cancer research.

[22]  P. Choyke,et al.  Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Y. Tanigawara,et al.  Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance , 2001, Japanese journal of cancer research : Gann.

[24]  J. Schneider,et al.  Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy , 2001, Breast Cancer Research.

[25]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[26]  J. Issakov,et al.  EFFECT OF P-GLYCOPROTEIN EXPRESSION ON OUTCOME IN THE EWING FAMILY OF TUMORS , 2001, Pediatric hematology and oncology.

[27]  E. Wiemer,et al.  Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer , 2000, Current opinion in oncology.

[28]  G. Gorodeski.  Calcium regulates estrogen increase in permeability of cultured CaSki epithelium by eNOS-dependent mechanism. , 2000, American journal of physiology. Cell physiology.

[29]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[30]  P. Meier,et al.  Expression of members of the multidrug resistance protein family in human term placenta. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[31]  D. Keppler,et al.  The Multidrug Resistance Protein 5 Functions as an ATP-dependent Export Pump for Cyclic Nucleotides* , 2000, The Journal of Biological Chemistry.

[32]  M. Kool,et al.  Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. , 2000, Cancer research.

[33]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[34]  D. Piwnica-Worms,et al.  Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. , 2000, Biochemical pharmacology.

[35]  E. D. de Vries,et al.  P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  P. D. Lee,et al.  MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Borst,et al.  ABC transporters in lipid transport. , 2000, Biochimica et biophysica acta.

[38]  F. Baas,et al.  Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Kool,et al.  Mutations in ABCC6 cause pseudoxanthoma elasticum , 2000, Nature Genetics.

[40]  S. Terry,et al.  Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum , 2000, Nature Genetics.

[41]  S. Sun,et al.  Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. , 2000, Cancer letters.

[42]  A. Lumsden,et al.  Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum , 2000, Journal of Molecular Medicine.

[43]  M. Lebwohl,et al.  Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  L. Möllgård,et al.  P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. Fisher,et al.  Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. , 2000, European journal of cancer.

[46]  I. Pastan,et al.  Decreased accumulation of [14c]carboplatin in human cisplatin‐resistant cells results from reduced energy‐dependent uptake , 2000, Journal of cellular physiology.

[47]  Z. Sauna,et al.  Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Nesland,et al.  P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. , 2000, Anticancer research.

[49]  P. Sonneveld,et al.  The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. , 2000, International journal of clinical pharmacology and therapeutics.

[50]  P. Westervelt,et al.  Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[52]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[53]  M. Burt,et al.  Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  A. G. de Boer,et al.  The role of P‐glycoprotein in blood‐brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice , 1999, British journal of pharmacology.

[55]  J. Schuetz,et al.  MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs , 1999, Nature Medicine.

[56]  J Verweij,et al.  Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. , 1999, Anti-cancer drugs.

[57]  O. Legrand,et al.  Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. , 1999, Blood.

[58]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[59]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[60]  G. Kruh,et al.  MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. , 1999 .

[61]  I. Pastan,et al.  Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. , 1999, Blood.

[62]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[63]  R. Kerbel,et al.  Adhesion-dependent multicellular drug resistance. , 1999, Anti-cancer drug design.

[64]  A. Sartorelli,et al.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  T. Voskoglou-Nomikos,et al.  Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  P. Sonneveld,et al.  Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? , 1999, Leukemia.

[67]  M. Baccarani,et al.  P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications , 1999, British journal of haematology.

[68]  I. Pastan,et al.  Studies of Human MDR1-MDR2 Chimeras Demonstrate the Functional Exchangeability of a Major Transmembrane Segment of the Multidrug Transporter and Phosphatidylcholine Flippase , 1999, Molecular and Cellular Biology.

[69]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[71]  S. Cole,et al.  Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. , 1998, Cancer research.

[72]  R. Arceci,et al.  Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  D. Hipfner,et al.  Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP). , 1998, British Journal of Cancer.

[74]  Richard J. Thompson,et al.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.

[75]  B. Sorrentino,et al.  Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. , 1998, Blood.

[76]  V. Ling,et al.  Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. , 1998, Cancer research.

[77]  D. Hipfner,et al.  Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  E K Rowinsky,et al.  Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  J. Schneider,et al.  Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. , 1998, Anticancer Research.

[80]  L. Goldstein,et al.  Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[82]  P. Meier,et al.  The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver* , 1998, The Journal of Biological Chemistry.

[83]  D. Bell,et al.  Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. , 1998, Cancer research.

[84]  I. Pastan,et al.  Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. , 1998, Biochemistry.

[85]  H. Kim,et al.  Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  A. E. Senior,et al.  P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites. , 1998, Biochemistry.

[87]  I. Pastan,et al.  Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. , 1998, Cancer research.

[88]  P. Bosma,et al.  Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[89]  T. Grogan,et al.  P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. , 1997, Journal of the National Cancer Institute.

[90]  J. Beijnen,et al.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.

[91]  Jos H. Beijnen,et al.  Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein , 1997, Nature Medicine.

[92]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[93]  R. Pirker,et al.  Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[94]  T. Lampidis,et al.  Multidrug-resistant gene expression in small-cell lung cancer. , 1997, American journal of clinical oncology.

[95]  J. Foekens,et al.  The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. , 1997, British Journal of Cancer.

[96]  B. Trock,et al.  Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. , 1997, Journal of the National Cancer Institute.

[97]  M. Kool,et al.  A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin‐Johnson syndrome , 1997, Hepatology.

[98]  E. Estey,et al.  Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[100]  T. Fojo,et al.  Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[102]  J. Dobkin,et al.  Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  A. Dantzig,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. , 1996, Cancer research.

[104]  E. Solary,et al.  Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. , 1996, Blood.

[105]  G. Dekan,et al.  MRP and MDR1 gene expression in primary breast carcinomas. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  Costan,et al.  Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.

[107]  D. Kerr,et al.  Clinical trials of P-glycoprotein reversal in solid tumours. , 1996, European journal of cancer.

[108]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[109]  B. Sikic,et al.  Pharmacological considerations in the modulation of multidrug resistance. , 1996, European journal of cancer.

[110]  D. Keppler,et al.  Absence of the canalicular isoform of the MRP gene–encoded conjugate export pump from the hepatocytes in Dubin‐Johnson syndrome , 1996, Hepatology.

[111]  F. Ognibene,et al.  Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  R. Evers,et al.  Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.

[113]  D. Keppler,et al.  Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. , 1996, Cancer research.

[114]  P. Houghton,et al.  P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[116]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[117]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[118]  B. Sikic,et al.  Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. , 1995, Journal of the National Cancer Institute.

[119]  P. Sonneveld,et al.  Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  G. Giaccone,et al.  Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. , 1995, Journal of the National Cancer Institute.

[121]  W. Wilson,et al.  Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  B. Sikic,et al.  Clinical studies with modulators of multidrug resistance. , 1995, Hematology/oncology clinics of North America.

[123]  S. Mineishi,et al.  Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. , 1995, Blood.

[124]  P. Borst,et al.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[125]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[126]  P. Gros,et al.  Phosphatidylcholine translocase: A physiological role for the mdr2 gene , 1994, Cell.

[127]  P. Sonneveld,et al.  Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. , 1994, Leukemia.

[128]  B. Sikic,et al.  Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  P. Borst,et al.  Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease , 1993, Cell.

[130]  D. Keppler,et al.  Differential inhibition by cyclosporins of primary‐active ATP‐dependent transporters in the hepatocyte canalicular membrane , 1993, FEBS letters.

[131]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[132]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[133]  W. Dalton,et al.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  P. Corris,et al.  Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. , 1993, British Journal of Cancer.

[135]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[136]  B. Sikic,et al.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  P. Sonneveld,et al.  Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.

[138]  I. Pastan,et al.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.

[139]  B. Chauffert,et al.  Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM , 1991, Cancer.

[140]  I. Roninson,et al.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.

[141]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[142]  V. Ling,et al.  Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  M. Tonato,et al.  Pharmacokinetics of vincristine in cancer patients treated with nifedipine , 1989, Cancer.

[144]  E. Beutler.  Consensus recommendations , 1989, Infection Control & Hospital Epidemiology.

[145]  I. Pastan,et al.  Expression of Multidrug Resistance Gene in Human Cancers , 1989 .

[146]  N. Mulder,et al.  PHARMACOKINETICS OF VINCRISTINE , 1988 .

[147]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[148]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[149]  D. Housman,et al.  Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins , 1986, Cell.

[150]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[151]  K. Danø.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.

[152]  D. Kerr,et al.  The effect of verapamil on the pharmacokinetics of adriamycin , 2004, Cancer Chemotherapy and Pharmacology.

[153]  A. Jaffe,et al.  Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.

[154]  R E Durand,et al.  Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. , 2001, Methods in cell biology.

[155]  R. Kim,et al.  Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. , 2000, Molecular pharmacology.

[156]  L. Doyle,et al.  Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. , 2000, Blood.

[157]  M. Grever,et al.  Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR 1 / P-Glycoprotein , MRP 1 , and LRP in Acute Myeloid Leukemia . A Southwest Oncology Group Study , 1999 .

[158]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[159]  T. Litman,et al.  Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. , 1999, Blood.

[160]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[161]  M. Kool,et al.  Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. , 1999, Cancer research.

[162]  R. Advani,et al.  Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). , 1999, Blood.

[163]  E. Franssen,et al.  99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. , 1998, British Journal of Cancer.

[164]  C. Shih,et al.  Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. , 1997, Advances in enzyme regulation.

[165]  Y. Sugiyama,et al.  Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. , 1997, The American journal of physiology.

[166]  S. Kohno,et al.  The clinical role of MDR1 gene expression in human lung cancer. , 1997, Anticancer research.

[167]  T. L. Lloyd,et al.  Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[168]  A. W. Boersma,et al.  Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[169]  J S Lee,et al.  Reversal of multidrug resistance. , 1994, Progress in clinical and biological research.

[170]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[171]  I. Pastan,et al.  Expression of the Multidrug Resistance Gene in Human Cancer , 1991 .

[172]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[173]  R. Benjamin,et al.  Combination chemotherapy in the management of disseminated soft tissue sarcomas - A southwest oncology group (SWOG) study , 1979 .